<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971630</url>
  </required_header>
  <id_info>
    <org_study_id>MyVENT1</org_study_id>
    <nct_id>NCT03971630</nct_id>
  </id_info>
  <brief_title>Tele-monitoring of Patients With Home Mechanical Ventilation (HMV) Trough Telemedicine System (MyVENT)</brief_title>
  <acronym>MyVENT</acronym>
  <official_title>Tele-monitoring of Patients With Home Mechanical Ventilation. &quot;MyVENT&quot; Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació Eurecat</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sociedad Española de Neumología y Cirugía Torácica</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to improve HMV treatment adherence using an integrated&#xD;
      telemedicine platform (MyVENT system)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a study to evaluate the effect of using tele-monitoring in the&#xD;
      follow-up of patients with HMV in order to improve their compliance and evaluate its&#xD;
      cost-effectiveness. Telemedicine will be provided by an integrated platform composed by a&#xD;
      website and a smartphone application for achieve a real feedback between patients and&#xD;
      clinicians.&#xD;
&#xD;
      Design: Prospective randomized clinical study that will include 184 patients with HMV. The&#xD;
      study will be divided in two phases, the first one consisting on the website and App system&#xD;
      development and the second one consisting on a clinical trial where the two follow-up systems&#xD;
      (standard care vs MyVENT group) will be compared.&#xD;
&#xD;
      Randomization: Patients will be randomised into two groups, HMV treatment management with&#xD;
      standard care vs. telemedicine follow up.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Group 1:MyVENT group: patients will be followed up by tele-monitoring support. MyVENT System&#xD;
      will be updated with data extracted from the ventilation equipment. This information and the&#xD;
      results of the complementary tests will be sent to the clinician.&#xD;
&#xD;
      Moreover, with MyVENT APP patients will receive information about their treatment and advices&#xD;
      to improve therapy if needed.&#xD;
&#xD;
      Group 2: Standard care. In this group all the visits will be performed at hospital following&#xD;
      daily clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to HMV treatment.</measure>
    <time_frame>9 months</time_frame>
    <description>The number of treatment hours will be obtained by the system counter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment efficiency</measure>
    <time_frame>9 months</time_frame>
    <description>Reduce or maintain carbon dioxide (CO2) in the measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>9 months</time_frame>
    <description>In both arms the evaluation of the cost effectiveness will be made at the end of the study in each group including: (telemedicine cost, HMV carrying charge, number of visits and calls).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early detection of problems</measure>
    <time_frame>9 months</time_frame>
    <description>In MyVENT group the system will send notices to the clinician if it detects any problem in order to solve problems earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define the patient satisfaction</measure>
    <time_frame>9 months</time_frame>
    <description>The study will evaluate the experience of the patient in both follow-up models they will be asked about their satisfaction grade with the follow up care provided during the study using a questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Ventilatory Failure</condition>
  <arm_group>
    <arm_group_label>Standard care group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These patients will be followed by standard protocol in the Unit of HMV of the University Hospital of Santa María- University Hospital Arnau de Vilanova.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MyVENT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will be followed up using the telemedicine (MyVENT System and APP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telemedicine</intervention_name>
    <description>Patients will be followed up using the MyVENT System and APP</description>
    <arm_group_label>MyVENT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women over to 18 years old.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Good knowledge about the use of smartphones.&#xD;
&#xD;
          -  Patients with Chronic Obstructive Pulmonary Disease (COPD), obesity-hypoventilation&#xD;
             syndrome and chest wall disorders who had started HMV at least three months before&#xD;
             their inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic pathology limiting life expectancy less than 1 year.&#xD;
&#xD;
          -  Psychiatric limiting problems.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ferran Barbé Illa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spanish Respiratory Society</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ferran Barbe Illa, MD</last_name>
    <phone>+34 (973) 70 53 72</phone>
    <email>fbarbe.lleida.ics@gencat.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ferran Barbé Illa</last_name>
    <phone>+34 (973) 70 53 72</phone>
    <email>fbarbe.lleida.ics@gencat.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferran Barbe Illa, MD</last_name>
      <email>fbarbe.lleida.ics@gencat.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sociedad Española de Neumología y Cirugía Torácica</investigator_affiliation>
    <investigator_full_name>Ferran Barbe</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>HMV</keyword>
  <keyword>Tele-monitoring</keyword>
  <keyword>Telemedicine</keyword>
  <keyword>Chronic hypercapnic respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoventilation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

